ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
ENDONOVO THERAPEUTICS, INC.
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $135.08K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2009 to 2022
Gross margin
92.6%
Operating margin
-2411.7%
Net margin
-13649.2%
Growth rates
Compound annual growth to fiscal 2022
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +85.2% | -24.1% | – | +16.0% | |
| Gross profit | +115.7% | -16.7% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2013 | FY2017 | FY2022 | Trend |
|---|---|---|---|---|
| Return on equity | 88.0% | 119.4% | 77.1% | |
| Return on assets | -3814.0% | -438.5% | -1123.6% | |
| Current ratio | 0.00 | 0.01 | 0.00 | |
| Debt to equity | -0.01 | -0.00 | – | |
| Net debt to EBITDA | -0.02× | 0.01× | – | |
| Interest coverage | – | – | – | |
| Capex to revenue | – | – | – | |
| Diluted shares | 1M | 242M | 139M |
Cash use needs five years of cash flow figures
Endonovo Therapeutics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-13649.2%
×Asset turnover0.08×
×Equity multiplier-0.07×
=Return on equity, FY202277.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -13649.2% | 0.08× | -0.07× | 77.1% |
| FY2021 | -4247.2% | 0.03× | -0.15× | 20.6% |
| FY2020 | -238.6% | 0.06× | -0.17× | 2.3% |
| FY2019 | -5582.4% | 0.08× | -0.24× | 108.6% |
| FY2018 | -7729.5% | 0.02× | -0.42× | 61.5% |
| FY2015 | -158633.9% | 0.02× | -0.03× | 96.9% |
| FY2014 | -3966.2% | 0.41× | -0.01× | 21.7% |
| FY2013 | -12634.5% | 0.30× | -0.02× | 88.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2022 against fiscal 2021
3of 8 tests passed in fiscal 2022. Some tests lack the figures they need.
- ProfitableNet income above zero-$18.47M
- Cash generatingOperating cash flow above zero-$678.84K
- Return on assets improvedROA up on the prior year-119.1% → -920.4%
- Earnings backed by cashOperating cash flow above net income-$678.84K vs -$18.47M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.01 → 0.00
- No dilutionShare count did not rise60M → 139M
- Gross margin improvedGross margin up on the prior year79.50% → 92.62%
- More efficientAsset turnover rose0.03 → 0.07